(Total Views: 609)
Posted On: 02/04/2021 6:55:16 PM
Post# of 148941
Indeed if LL suppresses PDL1 in cancer cells completely then no need for Opdivo.
But that possibility is so ridiculous, so preposterous, so improbable that it hardly makes sense to consider.
It is right there in the journal article. Maraviroc did suppress PDL1 expression by cancer cells.
Opdivo is $7 billion per year.
Replace it and CYDY gets $70 billion worth of market cap.
That's $120 per share.
Probably you don't even need to replace Opdivo to get the $70 billion market cap. Probably combo therapy with Opdivo in all Opdivo indications will get the $70 billion market cap.
This is completely new news for me.
No one has ever suggested LL could combo, let alone replace, Opdivo.
I maintain that Pourhassan does not know this.
Seems to me Cytodyn needs an R&D department.
Obviously not going to replace Opdivo on one journal article, but jeez this is a completely different MOA, completely different pathway than anything ever discussed publicly by anyone at Cytodyn.
But that possibility is so ridiculous, so preposterous, so improbable that it hardly makes sense to consider.
It is right there in the journal article. Maraviroc did suppress PDL1 expression by cancer cells.
Opdivo is $7 billion per year.
Replace it and CYDY gets $70 billion worth of market cap.
That's $120 per share.
Probably you don't even need to replace Opdivo to get the $70 billion market cap. Probably combo therapy with Opdivo in all Opdivo indications will get the $70 billion market cap.
This is completely new news for me.
No one has ever suggested LL could combo, let alone replace, Opdivo.
I maintain that Pourhassan does not know this.
Seems to me Cytodyn needs an R&D department.
Obviously not going to replace Opdivo on one journal article, but jeez this is a completely different MOA, completely different pathway than anything ever discussed publicly by anyone at Cytodyn.
(1)
(0)Scroll down for more posts ▼
